Linda M.P. Wesselman

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results

BackgroundWe aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.MethodsThe SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure is clinical progression.ResultsCross-sectional evaluation of the first 151 participants (age 64 ± 8, 44% female, Mini-Mental State Examination 29 ± 2) showed that 28 (25%) had preclinical Alzheimer’s disease (AD) (amyloid status available n = 114 (75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were associated with worse objective performance. The SCD-plus criteria age ≥ 60 (OR 7.7 (95% CI 1.7–38.9)) and apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6–15.0)) were associated with preclinical AD.ConclusionsThe SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD. Further inclusion and follow-up will address important questions related to SCD.

AMYLOID-β LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE

O2-06-03 AMYLOID-b LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE Sander C. J. Verfaillie, Tessa Timmers, Rosalinde E. R. Slot, Chris W. J. van der Weijden, Linda M. P. Wesselman, Niels D. Prins, Sietske A. M. Sikkes, Adriaan A. Lammertsma, Philip Scheltens, Rik Ossenkoppele, Bart N. M. van Berckel, Wiesje M. Van der Flier, VU University Medical Center, Amsterdam, Netherlands; Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, Netherlands; Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, Netherlands; Harvard Medical School, Boston University, Boston, MA, USA; Neuroscience Campus Amsterdam, Amsterdam, Netherlands; VU University Medical Center, Amsterdam Neuroscience, Amsterdam, Netherlands; Lund University, Lund, Sweden; Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, Netherlands. Contact e-mail: s.verfaillie@vumc.nl

Wishes and preferences for an online lifestyle program for brain health—A mixed methods study

Individuals with subjective cognitive decline (SCD) are at increased risk of Alzheimers disease and could benefit from a prevention strategy targeting lifestyle factors. Making a program available through the Internet gives a widespread reach at low cost, but suboptimal adherence is a major threat to effectiveness. As a first step in developing an online lifestyle program (OLP), we aimed to identify factors that are barriers and/or facilitators for the use of an OLP in individuals with SCD in three European countries.

Computer-assisted prediction of clinical progression in the earliest stages of AD

Individuals with subjective cognitive decline (SCD) are at increased risk for clinical progression. We studied how combining different diagnostic tests can help to identify individuals who are likely to show clinical progression.

PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM

Ressources et de Recherche, Nice University Hospital, Nice, France; Tours University Hospital, Tours, France; CIC1401, Clinical Epidemiology, Bordeaux, France; CATI – Centre d’Acquisition et de Traitement des Images, Paris, France; Sorbonne Universit es, UPMC University, Paris 06, INSERM, CNRS, Institut du Cerveau et la Moelle (ICM), AP-HP Hôpital Piti e-Salpêtri ere, Paris, France; Centre INSERM U1219, Bordeaux, France. Contact e-mail: genevieve.chene@u-bordeaux.fr